Analyzing the pivotal trial that compared sunitinib and IFN-α in renal cell carcinoma, using a method that assesses tumor regression and growth.
about
A Phase II study of Dovitinib in Patients With Recurrent or Metastatic Adenoid Cystic Carcinoma.Predicting survival of pancreatic cancer patients treated with gemcitabine using longitudinal tumour size data.Continuing a cancer treatment despite tumor growth may be valuable: sunitinib in renal cell carcinoma as example.A case study on the potential angiogenic effect of human chorionic gonadotropin hormone in rapid progression and spontaneous regression of metastatic renal cell carcinoma during pregnancy and after surgical abortion.Volumetric Tumor Response and Progression in EGFR-mutant NSCLC Patients Treated with Erlotinib or GefitinibComparative Effects of CT Imaging Measurement on RECIST End Points and Tumor Growth Kinetics Modeling.When progressive disease does not mean treatment failure: reconsidering the criteria for progression.Estimation of renal cell carcinoma treatment effects from disease progression modelingVolumetric tumor growth in advanced non-small cell lung cancer patients with EGFR mutations during EGFR-tyrosine kinase inhibitor therapy: developing criteria to continue therapy beyond RECIST progressionTumor growth rate is an early indicator of antitumor drug activity in phase I clinical trialsSimplifying the complexity of resistance heterogeneity in metastasisThe VEGF inhibitor axitinib has limited effectiveness as a therapy for adrenocortical cancer.Evaluation of tumor size response metrics to predict survival in oncology clinical trials.Optimizing oncology therapeutics through quantitative translational and clinical pharmacology: challenges and opportunities.Romidepsin is effective and well tolerated in older patients with peripheral T-cell lymphoma: analysis of two phase II trials.Sunitinib: Ten Years of Successful Clinical Use and Study in Advanced Renal Cell Carcinoma.Modeling and simulations relating overall survival to tumor growth inhibition in renal cell carcinoma patients.A new mathematical pharmacodynamic model of clonogenic cancer cell death by doxorubicin.Changing T-cell enigma: cancer killing or cancer control?Neutral evolution of drug resistant colorectal cancer cell populations is independent of their KRAS status.On the relationship between tumour growth rate and survival in non-small cell lung cancer.Model-based drug development in oncology: what's next?
P2860
Q30252721-8A7D4196-E53C-4E98-8A48-BCA661EEBBE8Q31052763-D1F04CC1-7205-4094-9FE6-4B33600E37FAQ33567889-D4C1A5FD-3D5D-4026-9422-1E7BAAA99B29Q35878497-C3A51B50-A14A-4B56-9A05-570A6226ABE4Q36553854-7BBA164C-0067-447E-A986-128CD65E65FBQ36599208-C536FFAE-D1CE-40CF-BB4F-AF1EDF51CAA3Q37003248-8F23AA39-FAB9-43F3-AFA5-E8BB3A2E3216Q37217573-5D35C5B3-8EF8-46D1-B75F-FA12EBA96023Q37280018-CEF00052-CF53-44C9-9FFB-8573C090C271Q37626194-3FD0CF95-06D1-428E-BC21-829D2526D35DQ37655188-A3E8B986-E330-4258-8574-70849399F872Q37681171-13AE5767-A066-407D-B3E6-53062E24C29EQ38178093-F51B0414-02F4-4D20-887A-5736E3410C47Q38351470-1B2BE243-28AA-4035-9E91-B34C491B7DDAQ38379898-D8B0C1DD-7A15-4A74-A486-E480B2B3A42BQ38799848-A3C45802-E71A-4978-9B05-90B76FBE8CD0Q38982360-D0181497-DA6D-45E5-97EC-3B2EB794E367Q39124331-107BE091-4127-43E7-950D-922982616819Q42287317-F57FF4E6-8FF1-4D81-A722-2207E5A9F9D6Q42370649-5A284C2A-8B8C-4686-B5EE-9C189A7A6702Q47151204-0BE9E1C7-4144-4F5A-B7FF-98ECDF0E1DF3Q50752919-94E7463B-FB31-4566-AC97-9E1AC61EE782
P2860
Analyzing the pivotal trial that compared sunitinib and IFN-α in renal cell carcinoma, using a method that assesses tumor regression and growth.
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
2012年论文
@zh
2012年论文
@zh-cn
name
Analyzing the pivotal trial th ...... s tumor regression and growth.
@ast
Analyzing the pivotal trial th ...... s tumor regression and growth.
@en
type
label
Analyzing the pivotal trial th ...... s tumor regression and growth.
@ast
Analyzing the pivotal trial th ...... s tumor regression and growth.
@en
prefLabel
Analyzing the pivotal trial th ...... s tumor regression and growth.
@ast
Analyzing the pivotal trial th ...... s tumor regression and growth.
@en
P2093
P2860
P1476
Analyzing the pivotal trial th ...... es tumor regression and growth
@en
P2093
Antonio Tito Fojo
Sindy T Kim
Susan E Bates
Wilfred D Stein
P2860
P304
P356
10.1158/1078-0432.CCR-11-2275
P407
P577
2012-02-17T00:00:00Z